adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.
Successful exit for HTGF: adivo joins Zoetis to bring the benefits of species-specific antibody therapies to pet owners worldwide
Info & Contact
Am Klopferspitz 19
82152 Martinsried/ Planegg